Interventions for Tuberculosis Control and Elimination 2002
Interventions for Tuberculosis Control and Elimination 2002
Interventions for Tuberculosis Control and Elimination 2002
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
843. Talic RF, Hargreve TB, Bishop MC, Kirk D, Prescott S. Intravesical Evans<br />
Bacille Calmette-Guérin <strong>for</strong> carcinoma in situ of the urinary bladder. Br J Urology<br />
1994; 73: 645-8.<br />
844. Wishahi MM, Ismail IMH, El-Sherbini M. Immunotherapy with bacille Calmette-<br />
Guérin in patients with superficial transitional cell carcinoma of the bladder associated<br />
with bilharziasis. Br J Urology 1994; 73: 649-54.<br />
845. Fellows GJ, Parmar MKB, Grigor KM, Hall RR, Heal MR, Wallace DMA.<br />
Marker tumour response to Evans <strong>and</strong> Pasteur Bacille Calmette-Guérin in multiple<br />
recurrent pTa/pTI bladder tumours: report from the Medical Research Council<br />
Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br<br />
J Urology 1994; 73: 639-44.<br />
846. Rogerson JW. Intravesical bacille Calmette-Guérin in the treatment of superficial<br />
transitional cell carcinoma of the bladder. Br J Urology 1994; 73: 655-8.<br />
847. Mack D, Frick J. Five-year results of a phase II study with low-dose Bacille<br />
Calmette-Guérin therapy in high-risk superficial bladder cancer. Urology 1995;<br />
45: 958-61.<br />
848. Witjes JA, van den Meijden APM, Collette L, Sylvester R, Debruyne FMJ, van<br />
Aubel A, Witjes WPJ. Long-term follow-up of an EORTC r<strong>and</strong>omized prospective<br />
trial comparing intravesical Bacille Calmette-Guérin-RIVM <strong>and</strong> mitomycin<br />
C in superficial bladder cancer. Urology 1998; 52: 403-10.<br />
849. Alex<strong>and</strong>roff AB, Jackson AM, O’Donnell MA, James K. BCG immunotherapy<br />
of bladder cancer: 20 years on. Lancet 1999; 353: 1689-94.<br />
850. Malström PU, Wijkström H, Lundholm C, Wester K, Bush C, Norlén BJ. 5year<br />
follow-up of a r<strong>and</strong>omized prospective study comparing mitomycin C <strong>and</strong><br />
Bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urology<br />
1999; 161: 1124-7.<br />
851. Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rümke P. Longterm<br />
adjuvant immunotherapy in stage I high risk malignant melanoma, comparing<br />
two BCG preparations versus non-treatment in a r<strong>and</strong>omised multicentre<br />
study. (EORTC Protocol 18781). Eur J Cancer 1993; 29A: 1237-42.<br />
852. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association<br />
between tuberculin responses <strong>and</strong> atopic disorders. Science 1997; 275: 77-9.<br />
853. Alm JS, Lilja G, Scheynus A. Early BCG vaccination <strong>and</strong> development of atopy.<br />
Lancet 1997; 350: 400-3.<br />
854. Aaby P, Shaheen SO, Heyes CB, Goudiaby A, Hall AJ, Shiell AW, Jensen H,<br />
Marchant A. Early BCG vaccination <strong>and</strong> reduction in atopy in Guinea-Bissau.<br />
Clin Experiment Allergy 2000; 30: 644-50.<br />
855. Barreto ML, Rodrigues LC, Silva PCR, Assis AMO, Reis MG, Santos CAST,<br />
Blanton RE. Lower hookworm incidence, prevalence, <strong>and</strong> intensitiy of infection<br />
in children with a Bacillus Calmette-Guérin vaccination scar. J Infect Dis 2000;<br />
182: 1800-3.<br />
226
Change language